RecruitingEarly Phase 1

Curcumin and EGCG Supplementation to Improve Serum BDNF and Mood Disturbance

United States64 participantsStarted 2024-09-30

Plain-language summary

The goal of this randomized placebo controlled trial is to examine mood disturbance and serum brain derived neurotrophic factor (BDNF) in people (age 18-50) with DASS-21 subscale scores \>9. The main questions it aims to answer are: Does curcumin and EGCG supplementation improve mood disturbance symptomology? Does curcumin and EGCG supplementation increase serum BDNF? Researchers will compare intervention versus placebo. Participants will consume an 8-week supplement of both: * 1,330mg/day curcumin * 350mg/day epigallocatechin gallate (EGCG)

Who can participate

Age range18 Years – 50 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adults age 18-50 * Depression subscale score of \>9/21 on the DASS-21 * No change in medications or supplements over the past 3 months * Can read and speak English Exclusion Criteria: * Currently consume curcumin or green tea daily * Currently, pregnant, nursing, or trying to become pregnant * Currently diagnosed with a perimenopausal disorder

What they're measuring

Changes in total distress as measured via DASS-21 total score.

Timeframe: 8-weeks

Changes in serum brain derived neurotrophic factor (BDNF).

Timeframe: 8-weeks

Trial details

NCT IDNCT06531863

SponsorAuburn University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-05-01

Contact for this trial

Aidan Cavanah, MSc

2057893258 amc0108@auburn.edu

View on ClinicalTrials.gov More Mood Disturbance trials